Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
13F holders, Q3 2025
Institutional positions in Calidi Biotherapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −12 vs. Q2 2025
- Shares held
- 232.5K
- −4.60K (−1.9%) vs. Q2 2025Converted for a 1-for-12 split
- Total value
- $353.6K
- −$300.3K (−45.9%) vs. Q2 2025
- New holders
- 5
- 9 more added
- Sold out
- 17
- 4 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $89.3K |
| Q1 2026 | 28 | $478.8K |
| Q4 2025 | 27 | $524.7K |
| Q3 2025 | 22 | $353.6K |
| Q2 2025 | 35 | $655.8K |
| Q1 2025 | 36 | $3.09M |
| Q4 2024 | 33 | $1.27M |
| Q3 2024 | 20 | $363.4K |
| Q2 2024 | 32 | $523.2K |
| Q1 2024 | 31 | $1.53M |
| Q4 2023 | 25 | $2.83M |
| Q3 2023 | 13 | $3.54M |
| Q2 2023 | 25 | $39.0M |
| Q1 2023 | 27 | $40.6M |
| Q4 2022 | 25 | $39.6M |
| Q3 2022 | 21 | $36.1M |
| Q2 2022 | 42 | $205.5M |
| Q1 2022 | 40 | $202.4M |
| Q4 2021 | 27 | $164.7M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Calidi Biotherapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Evermay Wealth Management LLC | 1 | $2 | 0.00% | −527−99.8% | ReducedConverted for a 1-for-12 split |
| JPMorgan Chase & Co | 9 | $14 | 0.00% | +4+71.4% | AddedConverted for a 1-for-12 split |
| Bank of America Corp | 30 | $46 | 0.00% | +3+10.4% | AddedConverted for a 1-for-12 split |
| CVA Family Office, LLC | 42 | $64 | 0.00% | +0+0.8% | AddedConverted for a 1-for-12 split |
| SBI Securities Co., Ltd. | 46 | $70 | 0.00% | −1−1.4% | ReducedConverted for a 1-for-12 split |
| Reyes Financial Architecture, Inc. | 100 | $152 | 0.00% | +100 | New |
| Tradewinds Capital Management, LLC | 101 | $154 | 0.00% | +18+21.2% | AddedConverted for a 1-for-12 split |
| FMR LLC | 125 | $190 | 0.00% | +125 | New |
| Advisor Group Holdings, Inc. | 400 | $377 | 0.00% | −1,829−82.1% | ReducedConverted for a 1-for-12 split |
| Barrett & Company, Inc. | 292 | $444 | 0.00% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Morgan Stanley | 387 | $588 | 0.00% | +227+142.0% | AddedConverted for a 1-for-12 split |
| Royal Bank of Canada | 417 | $1.00K | 0.00% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Highbridge Capital Management LLC | 1,042 | $1.58K | 0.00% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Apollo Management Holdings, L.P. | 1,042 | $1.58K | 0.00% | +1,042 | New |
| Finepoint Capital LP | 1,042 | $1.58K | 0.00% | 00.0% | UnchangedConverted for a 1-for-12 split |
| UBS Group AG | 2,564 | $3.90K | 0.00% | −1,178−31.5% | ReducedConverted for a 1-for-12 split |
| RS Crum Inc. | 15,256 | $23.2K | 0.01% | +15,256 | New |
| Warberg Asset Management LLC | 18,705 | $28.4K | 0.01% | +18,705 | New |
| Geode Capital Management, LLC | 29,595 | $45.0K | 0.00% | +10,214+52.7% | AddedConverted for a 1-for-12 split |
| Vanguard Group Inc | 34,728 | $52.8K | 0.00% | +5,280+17.9% | AddedConverted for a 1-for-12 split |
| Belpointe Asset Management LLC | 41,642 | $63.3K | 0.00% | +20,823+100.0% | AddedConverted for a 1-for-12 split |
| HighTower Advisors, LLC | 84,956 | $129.1K | 0.00% | +75,000+753.3% | AddedConverted for a 1-for-12 split |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −66,000−100.0% | Sold outConverted for a 1-for-12 split |
| Bank of Montreal | 0 | $0 | 0.00% | −35,208−100.0% | Sold outConverted for a 1-for-12 split |
| CPR Investments Inc. | 0 | $0 | 0.00% | −8,417−100.0% | Sold outConverted for a 1-for-12 split |
| Red Wave Investments LLC | 0 | $0 | 0.00% | −6,736−100.0% | Sold outConverted for a 1-for-12 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −5,933−100.0% | Sold outConverted for a 1-for-12 split |
| State Street Corp | 0 | $0 | 0.00% | −5,107−100.0% | Sold outConverted for a 1-for-12 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −4,058−100.0% | Sold outConverted for a 1-for-12 split |
| Drive Wealth Management, LLC | 0 | $0 | 0.00% | −3,750−100.0% | Sold outConverted for a 1-for-12 split |
| HRT Financial LP | 0 | $0 | 0.00% | −3,634−100.0% | Sold outConverted for a 1-for-12 split |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −2,592−100.0% | Sold outConverted for a 1-for-12 split |
| Delta Investment Management, LLC | 0 | $0 | 0.00% | −1,752−100.0% | Sold outConverted for a 1-for-12 split |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −1,100−100.0% | Sold outConverted for a 1-for-12 split |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −1,125−100.0% | Sold outConverted for a 1-for-12 split |
| Avidian Wealth Solutions, LLC | 0 | $0 | 0.00% | −833−100.0% | Sold outConverted for a 1-for-12 split |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −745−100.0% | Sold outConverted for a 1-for-12 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −853−100.0% | Sold outConverted for a 1-for-12 split |
| BlackRock, Inc. | 0 | $0 | 0.00% | −22−100.0% | Sold outConverted for a 1-for-12 split |
| Grassi Investment Management | – | – | – | – | Not filed |